None
Conditions
Interventions
Control group:The patient was given an infusion of 500ml of compound sodium lactate glucose injection (30 to 60 minutes after the infusion)
After the operation, 500ml of compound sodium lactate glucose injection was infused (30 to 60 minutes after the infusion).
Research group:The patient was given an infusion of 500ml of compound sodium acetate glucose injection (30 to 60 minutes after the infusion)
After the operation, 500ml of compound sodium acetate glucose injection was infused (30 to 60 minutes after the infusion).
Sponsors
Zhongda Hospital Southeast University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients who plan to undergo abdominal surgery under general anesthesia and need intestinal preparation according to preoperative requirements; 2.18 < age < 65 years old, gender is not limited; 3. The subjects fully understand the purpose and significance of the study, voluntarily participate in the study, voluntarily sign the informed consent letter, and voluntarily abide by the process of the study. The informed consent is signed by the subjects themselves or authorized clients.
Exclusion criteria
Exclusion criteria: 1.Patients with a history or current serious clinical illness of any of the following conditions that the investigator determined affected the study: (1) diabetes mellitus; (2) Chronic adrenal hypofunction; (3) Severe burns;( 4) hyperazotemia; (5) Abnormal parathyroid function; (6) Patients with cardiac insufficiency (class III-I according to the New York Heart Association [NYHA] classification); 2. Patients who are allergic to or have special reactions to either compound sodium acetate and glucose injection or compound sodium lactate and glucose injection; 3. Those whose laboratory test results met the following criteria during the screening period: 1) Serum potassium > 5.0mmol/L; 2) Serum phosphorus > 1.61mmol/L; 3) Serum calcium 1.25mmol/L; 5) Liver function (ALT, AST, ALP) > 2 times the upper limit of normal; 6) Renal function (urea, Cr) > 2 times the upper limit of normal; 4. Pregnant or lactating women who have sperm donation or fertility plans during the study period or 30 days after the end of the study and are unwilling or unable to take effective contraceptive measures; 5. The investigator assesses that the patient will not be able to complete the study as required or is not suitable to participate in the study for other reasons; 6. Participants who have participated in drug or device clinical studies within 3 months before randomization and have received drug or device treatment, or plan to participate in other clinical investigators during the study period; 7. Patients who have had nasogastric tube or nasojejunal tube placed before surgery, and need to have nasogastric tube or nasojejunal tube placed during or after surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EQ-5D-5L Health scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in biochemical markers (electrolytes, liver function, renal function, blood glucose);Changes in pH, PaCO?, HCO??, BE (Base Excess), and lactate;Time of first flatus and defecation after surgery; Time of water intake, resumption of liquid diet, and normal diet; Length of hospital stay.;The usage of medications such as insulin, potassium chloride injection, and sodium bicarbonate injection during surgery; The volume of intravenous fluids administered during surgery; | — |
Countries
China
Contacts
Public ContactXia Jiangyan
Zhongda Hospital Southeast University
Outcome results
None listed